Literature DB >> 32894535

Association between immunotherapy biomarkers and glucose metabolism from F-18 FDG PET.

B S Kim1, J Kang, S Jun, H Kim, K Pak, G H Kim, H J Heo, Y H Kim.   

Abstract

OBJECTIVE: To assess associations between parameters derived from F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and mRNA expression levels of immune checkpoint biomarkers such as programmed death receptor 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte antigen 4 (CTLA-4) as well as tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Integrated data were downloaded from Genomic Data Common Data Portal. Clinical, mRNA-seq, and whole exome-seq data of lung adenocarcinoma and squamous cell carcinoma from The Cancer Genome Atlas (TCGA) database were analyzed. TMB was defined as the total number of somatic missense mutations per megabase of the genome examined. Expression levels of PD-1, PD-L1, CTLA4 mRNA and TMB were collected. Correlations between imaging parameters of glucose metabolism and the expression levels of genomic biomarkers from cancers were evaluated. Bonferroni correction (adjusted p<0.0027) was applied to reduce type 1 error.
RESULTS: Of 31 NSCLC cases, 11 cases were adenocarcinoma (LUAD) and 20 were squamous cell carcinoma (LUSC). In linear regression analysis, texture parameters such as low gray-level run emphasis (LGRE, R2=0.48, p<0.0001), short run low gray-level emphasis (SRLGE, R2=0.45, p<0.0001) and long run low gray-level emphasis (LRLGE, R2=0.41, p=0.0001) derived from gray-level run length matrix (GLRLM) showed remarkable correlation with PD-L1 mRNA expression. Expression of PD-1, CTLA-4, and TMB failed to show any significant correlation with parameters of the F-18 FDG PET/CT.
CONCLUSIONS: Texture parameters derived from PET, known to indicate glucose uptake distribution, were correlated with expression of PD-L1 mRNA but not with expression of PD-1, CTLA-4 and TMB. Thus, tumoral heterogeneity could be a surrogate marker for the identification of PD-L1 level in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32894535     DOI: 10.26355/eurrev_202008_22625

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [18F]FDG PET/CT imaging: quantitative analysis of [18F]FDG uptake in primary tumors and metastatic lymph nodes.

Authors:  DaQuan Wang; Xu Zhang; Bo Qiu; SongRan Liu; Hui Liu; ChaoJie Zheng; Jia Fu; YiWen Mo; NaiBin Chen; Rui Zhou; Chu Chu; FangJie Liu; JinYu Guo; Yin Zhou; Yun Zhou; Wei Fan; Hui Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-11       Impact factor: 10.057

Review 2.  Radiomics in Oncological PET Imaging: A Systematic Review-Part 1, Supradiaphragmatic Cancers.

Authors:  David Morland; Elizabeth Katherine Anna Triumbari; Luca Boldrini; Roberto Gatta; Daniele Pizzuto; Salvatore Annunziata
Journal:  Diagnostics (Basel)       Date:  2022-05-27

Review 3.  Dysregulation of immune checkpoint proteins in hepatocellular carcinoma: Impact on metabolic reprogramming.

Authors:  Kanchan Vishnoi; Sandeep Kumar; Rong Ke; Ajay Rana; Basabi Rana
Journal:  Curr Opin Pharmacol       Date:  2022-05-05       Impact factor: 4.768

Review 4.  Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy.

Authors:  Laurent Dercle; Jeremy McGale; Shawn Sun; Aurelien Marabelle; Randy Yeh; Eric Deutsch; Fatima-Zohra Mokrane; Michael Farwell; Samy Ammari; Heiko Schoder; Binsheng Zhao; Lawrence H Schwartz
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

5.  Frontiers and hotspots of 18F-FDG PET/CT radiomics: A bibliometric analysis of the published literature.

Authors:  Xinghai Liu; Xianwen Hu; Xiao Yu; Pujiao Li; Cheng Gu; Guosheng Liu; Yan Wu; Dandan Li; Pan Wang; Jiong Cai
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.